A new trading day began on Monday, with Kyverna Therapeutics Inc. (NASDAQ: KYTX) stock price down -4.31% from the previous day of tradingbefore settling in for the closing price of $7.20. KYTX’s price has ranged from $6.30 to $35.06 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -37.90% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 96.28%. With a float of $17.68 million, this company’s outstanding shares have now reached $43.12 million.
In an organization with 96 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kyverna Therapeutics Inc. (KYTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Kyverna Therapeutics Inc. is 59.03%, while institutional ownership is 37.38%. The most recent insider transaction that took place on Feb 12 ’24, was worth 5,568,992. In this transaction 10% Owner of this company bought 253,136 shares at a rate of $22.00, taking the stock ownership to the 252,553 shares. Before that another transaction happened on Feb 12 ’24, when Company’s 10% Owner bought 450,000 for $22.00, making the entire transaction worth $9,900,000. This insider now owns 3,163,868 shares in total.
Kyverna Therapeutics Inc. (KYTX) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -26.86 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 96.28% per share during the next fiscal year.
Kyverna Therapeutics Inc. (NASDAQ: KYTX) Trading Performance Indicators
Here are Kyverna Therapeutics Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.63, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -4.00 in one year’s time.
Technical Analysis of Kyverna Therapeutics Inc. (KYTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.32 million. That was inferior than the volume of 0.49 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 23.56%. Additionally, its Average True Range was 0.61.
During the past 100 days, Kyverna Therapeutics Inc.’s (KYTX) raw stochastic average was set at 4.49%, which indicates a significant decrease from 13.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.89% in the past 14 days, which was lower than the 111.40% volatility it showed in the past 100 days.
However, in the short run, Kyverna Therapeutics Inc.’s stock first resistance to watch stands at $7.13. Second resistance stands at $7.38. The third major resistance level sits at $7.60. If the price goes on to break the first support level at $6.66, it is likely to go to the next support level at $6.44. The third support level lies at $6.19 if the price breaches the second support level.
Kyverna Therapeutics Inc. (NASDAQ: KYTX) Key Stats
With a market capitalization of 297.30 million, the company has a total of 43,115K Shares Outstanding. Currently, annual sales are 0 K while annual income is -60,370 K. The company’s previous quarter sales were 0 K while its latest quarter income was -28,800 K.
